The objective of this proof‐of‐concept pilot study was to assess whether Ktrans derived from DCE perfusion MR could help to distinguish HER2‐positive breast cancer brain metastases from HER2‐negative lesions. This evidence concerns the gene ERBB2 and breast cancer.